2. Avonex
Biogen Idec
2013 Revenue:
$3.00 billion

Once-weekly injectable Avonex was groundbreaking when it first grabbed the FDA's green light back in 1996. Now, however, with oral competition looming--including that from fellow Biogen ($BIIB) drug Tecfidera--the company has had to raise prices to keep sales growing.

In 2013, sales grew by 3.2%, with nearly two-thirds of its global haul generated in the U.S. The stateside revenue increase came primarily from price hikes; those were partially offset by an 8% decrease in unit sales volume, thanks partly to patients who switched to Biogen's new pill. And as Biogen said in its last 10-K, it only expects the competition to keep on building.

But as of August, Biogen has approval for a longer-lasting version of Avonex that will help it fight for its piece of the pie. Dubbed Plegridy, the drug requires injection only once every two weeks--a factor Biogen commercial chief Tony Kingsley recently told Reuters gives it "the potential to be the leading interferon on the market." -- Carly Helfand (email | Twitter)

For more:
Biogen ready to steal market share with newly minted MS drug Plegridy
Biogen Idec secures FDA nod for Avonex delivery accessory
Biogen Idec lengthens shelf life of Avonex


Suggested Articles

It’s been a rocky road for BMS’ immuno-oncology duo in previously untreated lung cancer, but a new addition to the regimen might hold the ticket.

Novartis’ Zolgensma launch has been anything but boring: First a record price, then a data scandal and now a manufacturing-related delay in Europe.

As CEO Paul Hudson focuses Sanofi's R&D program on immuno-oncology and gene therapies, Sanofi is readying a vaccine plant to make viral vectors.